Cardiovascular cell therapy - MG Biotherapeutics
Alternative Names: Adult stem cell therapy-heart failure - MG Biotherapeutics; Ventricular restoration cell therapy - MG BiotherapeuticsLatest Information Update: 04 Nov 2017
At a glance
- Originator MG-Biotherapeutics
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Ischaemic heart disorders
- No development reported Heart failure
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Heart-failure in France
- 04 Nov 2017 No recent reports of development identified for preclinical development in Ischaemic-heart-disorders in Canada (Injection)
- 27 Sep 2007 Data presented at the European Society of Cardiology Congress 2007 (ESC-2007) added to the Ischaemic heart disorders pharmacodynamics section